# An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma

> **NCT02219048** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 51 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Placebo
- **DRUG:** PF-03715455

## Key facts

- **NCT ID:** NCT02219048
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 51 (ACTUAL)
- **Why stopped:** The termination was due to business reasons. No safety or efficacy concerns contributed to the termination of the study
- **Last updated:** 2019-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02219048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02219048, "An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02219048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*